ALK-Abelló A/S (CPH:ALK.B)
234.00
+4.80 (2.09%)
At close: Apr 28, 2026
ALK-Abelló Revenue
In the year 2025, ALK-Abelló had annual revenue of 6.31B DKK with 14.00% growth. ALK-Abelló had revenue of 1.73B in the quarter ending December 31, 2025, with 15.61% growth.
Revenue
6.31B
Revenue Growth
+14.00%
P/S Ratio
8.21
Revenue / Employee
2.42M
Employees
2,613
Market Cap
51.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.31B | 775.00M | 14.00% |
| Dec 31, 2024 | 5.54B | 713.00M | 14.78% |
| Dec 31, 2023 | 4.82B | 313.00M | 6.94% |
| Dec 31, 2022 | 4.51B | 595.00M | 15.19% |
| Dec 31, 2021 | 3.92B | 425.00M | 12.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 309.06B |
| Coloplast | 27.89B |
| H. Lundbeck | 24.63B |
| Genmab | 23.66B |
| Demant | 22.97B |
| GN Store Nord | 16.78B |
| Zealand Pharma | 9.21B |
| Bavarian Nordic | 6.24B |
ALK-Abelló News
- 8 days ago - ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy - GlobeNewsWire
- 6 weeks ago - Annual General Meeting in ALK-Abelló A/S held on 16 March 2026 - GlobeNewsWire
- 6 weeks ago - ALK-Abelló Transcript: AGM 2026 - Transcripts
- 2 months ago - ALK-Abelló Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Invitation to the presentation of ALK's annual report 2025 on Friday, 20 February 2026 - GlobeNewsWire
- 3 months ago - ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children - GlobeNewsWire
- 5 months ago - ALK-Abelló Earnings Call Transcript: Q3 2025 - Transcripts
- 8 months ago - ALK-Abelló Earnings Call Transcript: Q2 2025 - Transcripts